Oconee Memorial Hospital
- Type
- Teaching hospital
- Where
- Seneca, SC
- Medicare CCN
- 420009
- Received
- $444,780 in 508 records, 2021 ($48,835 general, $395,945 research)
- Source
- CMS Open Payments search ↗
On this site
- Federal award recipient: OCONEE MEMORIAL HOSPITAL INC Fuzzy (name and state)
- Lobbying client: OCONEE MEMORIAL HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2021 | General payment | 20 | $48,835 |
| 2021 | Research payment | 488 | $395,945 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Aptevo Therapeutics Inc | 2 | $146,770 | 2021 |
| Abbott Laboratories | 24 | $106,407 | 2021 |
| Novo Nordisk AS | 435 | $91,117 | 2021 |
| Smith+Nephew, Inc. | 4 | $27,540 | 2021 |
| Janssen Research & Development, LLC | 19 | $24,025 | 2021 |
| Boston Scientific Corporation | 7 | $15,539 | 2021 |
| INSTYLLA, INC. | 1 | $10,650 | 2021 |
| Ethicon Inc. | 1 | $10,500 | 2021 |
| Siemens Medical Solutions USA, Inc. | 1 | $5,000 | 2021 |
| GE HEALTHCARE | 5 | $2,944 | 2021 |
| AstraZeneca Pharmaceuticals LP | 3 | $2,063 | 2021 |
| Linvatec Corporation | 1 | $1,406 | 2021 |
| Cook Research Incorporated | 2 | $340 | 2021 |
| AstraZeneca UK Limited | 1 | $238 | 2021 |
| Acerta Pharma LLC | 2 | $237 | 2021 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 488 | $395,945 |
| Grant | 4 | $31,000 |
| Long term medical supply or device loan | 2 | $10,652 |
| Debt forgiveness | 4 | $3,304 |
| Space rental or facility fees (teaching hospital only) | 8 | $2,698 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 2 | $1,180 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | Abbott Laboratories | $772 | Research payment | In-kind items and services | Dragonfly OCT Device, Vascular | FUSION | 2021 |
| 2021-12-31 | Abbott Laboratories | $620 | Research payment | In-kind items and services | Dragonfly OCT Device, Vascular | FUSION | 2021 |
| 2021-12-31 | AstraZeneca Pharmaceuticals LP | $30 | Research payment | In-kind items and services | CALQUENCE Drug, Oncology | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat | 2021 |
| 2021-12-31 | Acerta Pharma LLC | $12 | Research payment | In-kind items and services | CALQUENCE Drug, Oncology | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat | 2021 |
| 2021-12-30 | Ethicon Inc. | $10,500 | Research payment | Cash or cash equivalent | Research to further inform thinking about the role of LINX for Reflux Disease | 2021 | |
| 2021-12-30 | Novo Nordisk AS | $27 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-12-23 | Novo Nordisk AS | $27 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-12-23 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-12-23 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-12-23 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-12-23 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-12-23 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-12-23 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-12-23 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-12-23 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-12-23 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-12-23 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-12-23 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-12-23 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-12-23 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-12-23 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-12-23 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-12-23 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-12-23 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-12-23 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-12-23 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-12-23 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-12-23 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-12-23 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-12-23 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-12-23 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-12-23 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-12-23 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-12-22 | Novo Nordisk AS | $8,517 | Research payment | Cash or cash equivalent | NN1436-4625 | 2021 | |
| 2021-12-22 | Novo Nordisk AS | $911 | Research payment | Cash or cash equivalent | NN1436-4625 | 2021 | |
| 2021-12-17 | Smith+Nephew, Inc. | $25,000 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-12-15 | AstraZeneca Pharmaceuticals LP | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | FARXIGA Drug, Cardiovascular and Metabolism | 2021 | |
| 2021-12-10 | INSTYLLA, INC. | $10,650 | Research payment | Cash or cash equivalent | HES Embrace Device, Liquid Embolics for Interventional Radiology | Randomized Multi-Center, Subject and Evaluator Blinded, Parallel-Group Study to Evaluate the Safety and Effectiveness of | 2021 |
| 2021-12-10 | Novo Nordisk AS | $27 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-12-06 | Boston Scientific Corporation | $1,288 | Research payment | Cash or cash equivalent | DESBTK Device, Clinical Trial Product | RANGER II SFA | 2021 |
| 2021-12-06 | Boston Scientific Corporation | $93 | Research payment | Cash or cash equivalent | DESBTK Device, Clinical Trial Product | RANGER II SFA | 2021 |
| 2021-11-24 | Novo Nordisk AS | $10,025 | Research payment | Cash or cash equivalent | NN1436-4625 | 2021 | |
| 2021-11-22 | Janssen Research & Development, LLC | $925 | Research payment | Cash or cash equivalent | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locall | 2021 | |
| 2021-11-18 | Novo Nordisk AS | $27 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-11-17 | Acerta Pharma LLC | $225 | Research payment | Cash or cash equivalent | CALQUENCE Drug, Oncology | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat | 2021 |
| 2021-11-16 | Novo Nordisk AS | $5,280 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-11-16 | Novo Nordisk AS | $5,280 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-11-16 | Novo Nordisk AS | $2,640 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-11-16 | Novo Nordisk AS | $2,640 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-11-16 | Novo Nordisk AS | $27 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-11-02 | Abbott Laboratories | $200 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2021 | ||
| 2021-11-01 | Boston Scientific Corporation | $2,582 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | REPRISE IV | 2021 |
| 2021-11-01 | Boston Scientific Corporation | $682 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | REPRISE IV | 2021 |
| 2021-10-28 | Siemens Medical Solutions USA, Inc. | $5,000 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-10-28 | Janssen Research & Development, LLC | $923 | Research payment | Cash or cash equivalent | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locall | 2021 | |
| 2021-10-28 | Novo Nordisk AS | $27 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-10-27 | Novo Nordisk AS | $6,475 | Research payment | Cash or cash equivalent | NN1436-4625 | 2021 | |
| 2021-10-26 | Novo Nordisk AS | $1,188 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-10-26 | Novo Nordisk AS | $39 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-10-26 | Novo Nordisk AS | $39 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-10-26 | Novo Nordisk AS | $39 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-10-26 | Novo Nordisk AS | $39 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-10-26 | Novo Nordisk AS | $39 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-10-26 | Novo Nordisk AS | $39 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-10-26 | Novo Nordisk AS | $39 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-10-26 | Novo Nordisk AS | $39 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-10-26 | Novo Nordisk AS | $39 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-10-26 | Novo Nordisk AS | $39 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-10-26 | Novo Nordisk AS | $39 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-10-26 | Novo Nordisk AS | $39 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-10-26 | Novo Nordisk AS | $39 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-10-26 | Novo Nordisk AS | $39 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-10-26 | Novo Nordisk AS | $39 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-10-26 | Novo Nordisk AS | $39 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-10-26 | Novo Nordisk AS | $39 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-10-26 | Novo Nordisk AS | $39 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-10-26 | Novo Nordisk AS | $39 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-10-26 | Novo Nordisk AS | $39 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-10-26 | Novo Nordisk AS | $39 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-10-26 | Novo Nordisk AS | $39 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-10-26 | Novo Nordisk AS | $39 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-10-26 | Novo Nordisk AS | $39 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-10-26 | Novo Nordisk AS | $39 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-10-26 | Novo Nordisk AS | $39 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-10-19 | Aptevo Therapeutics Inc | $64,947 | Research payment | Cash or cash equivalent | APVO436 | 2021 | |
| 2021-10-15 | Novo Nordisk AS | $27 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-10-05 | Novo Nordisk AS | $27 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-10-04 | Janssen Research & Development, LLC | $918 | Research payment | Cash or cash equivalent | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locall | 2021 | |
| 2021-10-04 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-30 | Abbott Laboratories | $2,080 | Research payment | Cash or cash equivalent | Dragonfly OCT Device, Vascular | Validation of OCT-based FUnctional diagnoSIs of corONary stenosis | 2021 |
| 2021-09-27 | Novo Nordisk AS | $6,469 | Research payment | Cash or cash equivalent | NN1436-4625 | 2021 | |
| 2021-09-14 | Novo Nordisk AS | $219 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-14 | Novo Nordisk AS | $160 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-14 | Novo Nordisk AS | $160 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-14 | Novo Nordisk AS | $160 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-14 | Novo Nordisk AS | $160 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-14 | Novo Nordisk AS | $160 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-14 | Novo Nordisk AS | $160 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-14 | Novo Nordisk AS | $160 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-14 | Novo Nordisk AS | $160 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-14 | Novo Nordisk AS | $160 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-10 | Janssen Research & Development, LLC | $1,250 | Research payment | Cash or cash equivalent | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locall | 2021 | |
| 2021-09-10 | Janssen Research & Development, LLC | $150 | Research payment | Cash or cash equivalent | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locall | 2021 | |
| 2021-09-07 | Boston Scientific Corporation | $1,288 | Research payment | Cash or cash equivalent | DESBTK Device, Clinical Trial Product | RANGER II SFA | 2021 |
| 2021-09-07 | Boston Scientific Corporation | $250 | Research payment | Cash or cash equivalent | DESBTK Device, Clinical Trial Product | RANGER II SFA | 2021 |
| 2021-09-07 | Novo Nordisk AS | $35 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-07 | Novo Nordisk AS | $35 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-07 | Novo Nordisk AS | $35 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-07 | Novo Nordisk AS | $35 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-07 | Novo Nordisk AS | $35 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-07 | Novo Nordisk AS | $35 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-07 | Novo Nordisk AS | $35 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-07 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-03 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-03 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-03 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-03 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-03 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-03 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-03 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-03 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-03 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-03 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-03 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-03 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-03 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-03 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-03 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-03 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-03 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-03 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-03 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-03 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-03 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-03 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-03 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-03 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-09-03 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-08-30 | Novo Nordisk AS | $3,300 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-08-30 | Janssen Research & Development, LLC | $918 | Research payment | Cash or cash equivalent | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locall | 2021 | |
| 2021-08-25 | Novo Nordisk AS | $9,487 | Research payment | Cash or cash equivalent | NN1436-4625 | 2021 | |
| 2021-08-25 | Abbott Laboratories | $2,028 | Research payment | Cash or cash equivalent | Dragonfly OCT Device, Vascular | A Clinical Investigation to Assess the Abbott Next Generation Drug Eluting Stent48mm | 2021 |
| 2021-08-23 | Novo Nordisk AS | $80 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-08-23 | Novo Nordisk AS | $80 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-08-23 | Novo Nordisk AS | $80 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-08-23 | Novo Nordisk AS | $80 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-08-23 | Novo Nordisk AS | $80 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-08-23 | Novo Nordisk AS | $80 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-08-23 | Novo Nordisk AS | $80 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-08-23 | Novo Nordisk AS | $80 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-08-20 | Novo Nordisk AS | $27 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-08-18 | Novo Nordisk AS | $1 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-08-16 | Janssen Research & Development, LLC | $5,400 | Research payment | Cash or cash equivalent | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locall | 2021 | |
| 2021-08-16 | Janssen Research & Development, LLC | $1,250 | Research payment | Cash or cash equivalent | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locall | 2021 | |
| 2021-08-16 | Janssen Research & Development, LLC | $150 | Research payment | Cash or cash equivalent | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locall | 2021 | |
| 2021-08-11 | Abbott Laboratories | $3,880 | Research payment | Cash or cash equivalent | Dragonfly OCT Device, Vascular | Optical Coherence Tomography (OCT) Guided Coronary Stent Implantation Compared to Angiography: a Multicenter Randomized | 2021 |
| 2021-08-11 | AstraZeneca Pharmaceuticals LP | $533 | Research payment | Cash or cash equivalent | CALQUENCE Drug, Oncology | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat | 2021 |
| 2021-08-09 | Janssen Research & Development, LLC | $1,885 | Research payment | Cash or cash equivalent | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locall | 2021 | |
| 2021-08-04 | Abbott Laboratories | $200 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2021 | ||
| 2021-07-29 | Novo Nordisk AS | $27 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-07-26 | Novo Nordisk AS | $3,016 | Research payment | Cash or cash equivalent | NN1436-4625 | 2021 | |
| 2021-07-20 | Smith+Nephew, Inc. | $1,540 | Debt forgiveness | Cash or cash equivalent | GRAFIX PL Medical Supply, Other Advanced Wound Management | 2021 | |
| 2021-07-19 | Novo Nordisk AS | $1,320 | Research payment | In-kind items and services | NN1436-4625 | 2021 | |
| 2021-07-19 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN7415-4807 | 2021 | |
| 2021-07-19 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN7415-4807 | 2021 | |
| 2021-07-19 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN7415-4807 | 2021 | |
| 2021-07-19 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN7415-4807 | 2021 | |
| 2021-07-19 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN7415-4807 | 2021 | |
| 2021-07-19 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN7415-4807 | 2021 | |
| 2021-07-19 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN7415-4807 | 2021 | |
| 2021-07-19 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN7415-4807 | 2021 | |
| 2021-07-19 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN7415-4807 | 2021 | |
| 2021-07-19 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN7415-4807 | 2021 | |
| 2021-07-19 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN7415-4807 | 2021 | |
| 2021-07-19 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN7415-4807 | 2021 | |
| 2021-07-19 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN7415-4807 | 2021 | |
| 2021-07-19 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN7415-4807 | 2021 | |
| 2021-07-19 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN7415-4807 | 2021 | |
| 2021-07-19 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN7415-4807 | 2021 | |
| 2021-07-19 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN7415-4807 | 2021 | |
| 2021-07-19 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN7415-4807 | 2021 | |
| 2021-07-19 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN7415-4807 | 2021 | |
| 2021-07-19 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN7415-4807 | 2021 | |
| 2021-07-19 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN7415-4807 | 2021 | |
| 2021-07-19 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN7415-4807 | 2021 | |
| 2021-07-19 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN7415-4807 | 2021 | |
| 2021-07-19 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN7415-4807 | 2021 | |
| 2021-07-19 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN7415-4807 | 2021 | |
| 2021-07-19 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN7415-4807 | 2021 | |
| 2021-07-19 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN7415-4807 | 2021 | |
| 2021-07-19 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN7415-4807 | 2021 | |
| 2021-07-19 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN7415-4807 | 2021 | |
| 2021-07-19 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN7415-4807 | 2021 | |
| 2021-07-19 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN7415-4807 | 2021 | |
| 2021-07-19 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN7415-4807 | 2021 | |
| 2021-07-19 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN7415-4807 | 2021 | |
| 2021-07-19 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN7415-4807 | 2021 | |
| 2021-07-19 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN7415-4807 | 2021 | |
| 2021-07-19 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN7415-4807 | 2021 | |
| 2021-07-19 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | NN7415-4807 | 2021 |
The latest 200 records of 508.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Seneca, SC, county Oconee County, SC, state South Carolina; placed by its city name.
| Measure | Place (city or town) Seneca, SC | County Oconee County, SC | State South Carolina |
|---|---|---|---|
| Population B01003 | 8,993 | 80,469 | 5,296,225 |
| Population, 2020 census P1 | 8,850 | 78,607 | 5,118,425 |
| Median age B01002 | 39.6 | 47.3 | 40.2 |
| Under 18 B01001 | 18.5% | 19.1% | 21.4% |
| 65 and over B01001 | 20.4% | 24.9% | 18.9% |
| Households B11001 | 4,082 | 34,515 | 2,117,989 |
| Foreign born B05002 | 2.6% | 4.2% | 5.8% |
| Median household income B19013 | $52,022 | $62,388 | $69,324 |
| Median family income B19113 | $74,864 | $80,443 | $86,707 |
| Per capita income B19301 | $34,204 | $39,360 | $39,236 |
| Poverty rate B17001 | 22.1% | 17.6% | 14.1% |
| Unemployment rate B23025 | 8.9% | 5.9% | 4.9% |
| Civilian labor force B23025 | 4,606 | 35,647 | 2,560,429 |
| Mean commute (minutes) B08013 | 16.0 | 23.9 | 25.6 |
| Bachelor's degree or higher B15003 | 29.1% | 28.7% | 32.1% |
| Housing units B25001 | 4,648 | 42,100 | 2,443,039 |
| Owner-occupied B25003 | 51.4% | 76.2% | 71.9% |
| Renters B25003 | 48.6% | 23.8% | 28.1% |
| Median home value B25077 | $240,000 | $237,100 | $259,000 |
| Median gross rent B25064 | $807 | $881 | $1,180 |
| White, not Hispanic B03002 | 72.8% | 83.1% | 61.9% |
| Black B03002 | 17.4% | 5.2% | 24.6% |
| Hispanic or Latino B03002 | 6.4% | 6.2% | 7.4% |
| Asian B03002 | 0.8% | 0.7% | 1.7% |
| American Indian and Alaska Native B03002 | 0.8% | 0.4% | 0.2% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Seneca, SC.
Comments